Bausch + Lomb Launches Zenlens® ECHO™ Scleral Lenses in the United States

VAUGHAN, Ontario, May 7, 2024 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Zenlens ECHO, a non-prosthetic, custom scleral contact lens technology designed to fit a wide variety of corneal shapes and sizes, including patients who have advanced ocular conditions such as corneal degeneration and certain postoperative conditions.

“ECHO builds on our Zenlens specialty lens brand, providing eye care professionals with an additional level of customization for patients with advanced needs who require more specificity in their lens fitting,” said Yang Yang, president, Global Vision Care, Bausch + Lomb.

Unlike impression-based or freeform lenses that can be expensive and require additional training or equipment, Zenlens ECHO can be used with a variety of technologies already available in clinical practice, including a slit lamp, optical coherence tomography scanning, profilometry or a Bi-Elevation™ fitting set. There is no additional training or certification required.

“Fitting patients who have advanced ocular conditions can be extremely complex. Zenlens ECHO simplifies the process,” said Jason Jedlicka, O.D., associate professor and director of the Cornea and Contact Lens Service, Indiana University School of Optometry. “Having the ability to further customize my patients’ lens fits and achieve great outcomes without the high cost of a freeform design or high-end equipment fills an important need in my practice.” 

For more information on Zenlens ECHO, visit https://www.bauschsvp.com/lenses/zenlens-echo/.

###

Important Safety Information

WARNINGS:
Patients should be advised of the following warnings pertaining to contact lens wear:

  • Problems with contact lenses and lens care products could result in serious injury to the eye. It is essential that patients follow their eyecare practitioner’s directions and all labeling instructions for proper use of lenses and lens care products, including the lens case. Eye problems, including corneal ulcers, can develop rapidly and lead to loss of vision.
  • Daily wear lenses are not indicated for overnight wear, and patients should be instructed not to wear lenses while sleeping.
  • Clinical studies have shown that the risk of serious adverse reactions is increased when daily wear lenses are worn overnight.
  • Studies have shown that contact lens wearers who are smokers have a higher incidence of adverse reactions than nonsmokers.
  • If a patient experiences eye discomfort, excessive tearing, vision changes, or redness of the eye, the patient should be instructed to immediately remove lenses and promptly contact his or her eyecare practitioner.

CONTRAINDICATIONS:
Do not use when any of the following conditions exist:

  • Acute or subacute inflammation or infection of the anterior chamber of the eye
  • Any eye disease, injury or abnormality, other than keratoconus, PMD, that affects the cornea, conjunctiva or eyelids
  • Severe insufficiency of lacrimal secretion (dry eye)
  • Corneal hypoesthesia (reduced sensitivity), if not aphakic
  • Any systemic disease that may affect the eye or be exaggerated by wearing contact lenses
  • Allergic reactions of ocular surfaces or adnexa that may be induced or exaggerated by wearing contact lenses or using contact lens solutions
  • Allergy to any ingredient in a solution which is to be used to care for contact lenses
  • Any active corneal infection (bacterial, fungal or viral)
  • Red or irritated eyes

ADVERSE EFFECTS:
The following problems may occur with the use of contact lenses:

  • Eyes stinging, burning, itching, irritation or other eye pain
  • Comfort is less than when the lens was first placed on the eye
  • Feeling of something in the eye such as a foreign body, scratched area
  • Excessive watering (tearing) of the eye
  • Unusual eye secretions Redness of the eyes
  • Reduced sharpness of vision (poor visual acuity)
  • Blurred vision, rainbows, or halos around objects
  • Sensitivity to light (photophobia)
  • Dry eyes

About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on X, LinkedIn, Facebook and Instagram.

Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “will,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

© 2024 Bausch + Lomb.
 ALZN.0027.USA.24

Media Contact:
Kristy Marks
[email protected]
(908) 927-0683

Back to Press Releases